Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Last trade$1.54
Day change-$0.09 (-5.52%)
Day range$1.52 – $1.67
Volume715,979
Market cap$101M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$101.43M
Price / earnings
—
Price / book
0.75×
Price / sales
4.04×
EV / sales
2.11×
EV / EBITDA
-0.49×
Profitability
Earnings per share
-$1.68
Return on assets
-59.21%
Return on equity
-77.58%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.81×
Quick ratio
6.81×
Cash ratio
2.88×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$109.83M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VYGR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$4.01M
$3.17M
$2.59M
$15.34M
$13.37M
$5.2M
$6.47M
$6.28M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$4.01M
$3.17M
$2.59M
$15.34M
$13.37M
$5.2M
$6.47M
$6.28M
Selling, general and administrative
$6.07M
$7.52M
$8.26M
$9.32M
$8.09M
$10.5M
$9.64M
$8.99M
Research and development
$24.37M
$22.04M
$24.6M
$35.95M
$35.87M
$31.33M
$31.53M
$35.58M
Total operating expenses
$30.44M
$29.56M
$32.86M
$45.27M
$43.96M
$41.83M
$41.17M
$44.58M
Operating income
-$26.42M
-$26.39M
-$30.27M
-$29.93M
-$30.59M
-$36.63M
-$34.69M
-$38.3M
Interest expense
$1.34M
$1.53M
$0
$0
$2.39M
$2.83M
$0
$0
Income before taxes
-$24.68M
-$24.45M
-$27.92M
-$27.42M
-$27.81M
-$33.37M
-$30.98M
-$33.9M
Income taxes
$18K
$20K
$14K
$9K
$83K
$15K
$37K
$584K
Net income
-$24.69M
-$24.47M
-$27.94M
-$27.43M
-$27.89M
-$33.38M
-$31.02M
-$34.49M
Net income attributable to common shareholders
-$24.69M
-$24.47M
-$28.23M
-$27.43M
-$27.89M
-$33.38M
-$30.81M
-$34.49M
EBITDA
-$25.59M
-$25.48M
-$29.34M
-$28.88M
-$29.66M
-$35.56M
-$33.68M
-$37.29M
Basic earnings per share
-$0.40
-$0.40
-$0.47
-$0.47
-$0.47
-$0.57
-$0.53
-$0.59
Diluted earnings per share
-$0.40
-$0.40
-$0.47
-$0.47
-$0.47
-$0.57
-$0.53
-$0.59
Recent news
Company coverage with links to the original publishers.
Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.
Johnson & Johnson discontinued its Phase 2b AuTonomy study of posdinemab after the drug failed to show statistical significance in slowing clinical decline for early Alzheimer's disease patients.
Voyager Therapeutics expanded its Alzheimer's disease franchise by introducing a new gene therapy program targeting APOE, complementing existing tau and amyloid assets. The program aims to reduce APOE4 variant expression while delivering the protective APOE2 variant using an innovative IV-delivered TRACER capsid.
Voyager Therapeutics published data in Molecular Therapy demonstrating the ability of a novel AAV capsid, VCAP-102, to cross the blood-brain barrier and transduce various brain regions in rodents and non-human primates. The company also highlighted its next-generation CNS capsids and non-viral delivery approaches.
Voyager Therapeutics presented new preclinical data on its tau-targeting gene therapy VY1706 and anti-tau antibody VY7523 at the AD/PD™ 2025 conference. The data showed promising results in reducing tau levels and inhibiting tau spread in animal models, supporting the potential of these programs for the treatment of Alzheimer's disease.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.